|
|
The concept of Diabetes & CV risk: A lifetime risk challenge
|
|
|
|
The Cardiovascular Continuum
|
|
|
|
RAS Blockade Across the CV Continuum
|
|
|
|
2007 ESH/ESC Guidelines: Choice of Antihypertensive Drugs
|
|
|
|
VALUE : Odds Ratios Over Time
|
|
|
|
VALUE: Endpoints while on Monotherapy
|
|
|
|
LIFE: Primary Composite Endpoint
|
|
|
|
Risk Reduction: ARB versus Control
|
|
|
|
MOrbidity and Mortality after Stroke – Eprosartan vs. Nitrendipine in Secondary Prevention
|
|
|
|
SCOPE: First Major Cardiovascular Events
in Patients with a Previous Stroke
|
|
|
|
Antagonism of Angiotensin II-Induced Effects by Candesartan and Losartan
|
|
|
|
Insurmountable and Surmountable
Antagonism: Relation to Duration of Binding
|
|
|
|
A Placebo Controlled ABPM Comparison of Candesartan 8 mg and Losartan 50 mg
|
|
|
|
Candesartan Cilexetil vs Losartan : Mean Change From Baseline to Week 8 in Systolic ABP
|
|
|
|
Comparison of the Efficacy of Candesartan & Losartan: Meta-Analysis of Trials in the Treatment of Hypertension
|
|
|
|
Candesartan & Losartan-Antihypertensive Effects: Systolic BP in Direct Comparator Trials
|
|
|
|
Candesartan & Losartan-Antihypertensive Effects: Systolic BP in Direct Comparator Trials
|
|
|
|
Candesartan & Losartan-Antihypertensive Effects: Diastolic BP in Direct Comparator Trials
|
|
|
|
Potential Benefits of Additional BP Reductions
|
|
|
|
Hypothesis and Aim
|
|
|
|
Selection Method
|
|
|
|
The “Real-Life” Study: Candesartan v Losartan
|
|
|
|
Blood Pressure Reduction
|
|
|
|
Concomitant Medication
|
|
|
|
Primary Outcome: Candesartan v Losartan
|
|
|
|
Risk of Separate Endpoints
|
|
|
|
Candesartan v Losartan: Mortality in Heart Failure Patients
|
|
|
|
Candesartan v Losartan: Mortality in Heart Failure Patients
|
|
|
|
Candesartan v Losartan: Mortality in Heart Failure Patients
|
|
RAS blockade in the real world.dr meredith (PPTX 1.7MB)
Share this page with your colleagues and friends: